Biotechnology in South Korea

Boditech Med Inc

Boditech Med Inc. is a biotechnology company based out of 1144 - 2 Gerdu-ri, Dongnae-myeon, CHUNCHON, South Korea.

501 to 1000 staff

Bioneer Corporation

Bioneer Corporation is the first Korean biotechnology company established in 1992. The company has developed state of art molecular biology products and technologies including oligonucleotides, th.

11 to 50 staff

Icgm

AAV - Lentivirus - Retrovirus - Non-GMP site Engineering run - rcAAV - RCL

11 to 50 staff

Olipass Corporation

2006 PNA(Peptide Nucleic Acid). RNA. RNA. OliPass PNA. We are living in remarkable times, in fact when you think about it, over the past 100 years the life expectancy around the globe has almost doubled and we continue, of course, to constantly hope for even greater longevity. But we need to ask ourselves, does this increased longevity lead to a happier life? We all agree that true happiness does not result from just living longer, but also from living well. At OliPass, our mission is to open the door to a new era of healthy and beautiful aging. Since 2006, OliPass has been committed to revolutionizing the life sciences and improving the quality of life. Our research is focused on developing a new generation of therapeutics using our novel PNA based technologies. Thanks to our dedicated team and their hard work, OliPass is now a leading biotech company with OliPass PNA Platform Technology and a growing presence throughout the globe. At OliPass, scientists from diverse fields are constantly working together to find the cures for all diseases. With our innovative OliPass PNA platform technology, our goal is to make the highest quality of science affordable and accessible, so that everyone around the world can enjoy a happy, healthy life. OliPass is dedicated to providing safe and feasible options for healthy aging.

51 to 200 staff

Bio3s

To develop a technology that responds to the demand of consumers who want to collect SARSCoV-2 samples without pain, BIO3S, Inc. has a novel "Oral and Nasal Virus Clinical Collection(OVC) technology", for highly sensitive self-diagnosis of COVID-19. The Salivfix solution is onestep technology that does not require additional steps such as antigen extract step and RNA extraction step in an antigen rapid diagnostic tests (Ag-RDTs) and PCR analysis, respectively. BIO3S, Inc. completed clinical trial in comparing the sensitivity and specificity of collecting virus from COVID-19 patients' mouth using OVC technology, in comparison to collecting virus with conventional nasopharyngeal swab (NPS). We hope our OVC technology leads the self-testing market to diagnosis of respiratory viral infectious disease.

11 to 50 staff

Polus Inc

POLUS Inc, mainly based in Republic of Korea, aims to contribute to Global Medical Equality with affordable biopharmaceutical products. It is our mission to transform the paradigm of the biopharmaceutical industry standards by making high quality biological drugs at an affordable price for all patients in the world. With our potential and expertise in all areas of biopharmaceutics, we promise to become a global biopharmaceutical company and lead this industry to contribute to Global Medical Equality. Come visit our website for more information!

201 to 500 staff

Biospectator Inc

BioSpectator is first news media focused on biotech industry in a South Korea. BioSpectator provide latest information on biotechnology company, new drug, pipeline, clinical trials and more for professionals and decision makers within biotech industry.

1 to 10 staff

Delvine

Delvine is a developer of digital therapeutics intended to provide solutions for physical and psychological rehabilitation using the brain plasticity mechanism. It aims to systematically modify brain systems responsible for the physical and psychological problems by offering individualized game-type contents via platforms such as virtual reality, augmented reality, and mobile applications. It will change the effort-consuming experiences of conventional treatment into new experiences of fun and easy-accessible therapeutics. Users can recover by just enjoying the games tailored to each one of them.|()''.''/''.

11 to 50 staff

Ichrogene

Dna db 2./.

1 to 10 staff

Labex

11 to 50 staff

C&l Therapeutics, Inc

C&L Therapeutics is a preclinical stage biotech company focused on developing innovative therapeutics for the treatment of cancers and neuromuscular diseases with a proprietary small molecule STAR platform library to modulate RNA biology. Our flagship pipeline CL101 (Immune Checkpoint Inhibitor (ICI) booster), which we have developed in strategic collaboration with Jubilant Biosys, is a multikinase inhibitor targeting specific spectrum of oncogenic Receptor Tyrosine Kinases (RTKs) and GSK-3 with a potential to augment the anti-tumor effects by enhancing T-cell responses through the transcriptional inhibition of PD-1 and LAG-3 when combined with immune checkpoint Inhibitors (ICPI) such as Keytruda and Opdivo. In particular, CL101 can effectively reverses the loss of skeletal muscle protein and recovers the muscle strength in animal studies, paving the way to develop next-generation cancer therapy to address the low-response rate of CPI and high prevalence of cachexia in cancer patients. We also develop a direct cell reprogramming agent to generate clinically relevant cell types from patient-derived differentiated somatic cells via "trans-differentiation". This approach can provide a powerful tool for regenerative, precision medicine.

1 to 10 staff

Sesil Corporation

1 to 10 staff

Therna Therapeutics

We deliver therapeutic RNAs to targeted tissues.

11 to 50 staff

Abtis 앱티스

AbTis is a biotechnology company with a proprietary linker platform, AbClick®, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads. Through AbClick®, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick® also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing optimal bioconjugate therapies. AbClick® is applicable to the native, commercial off-the-shelf, or novel antibodies under development as it requires no mutation or engineering to the antibody itself. Core competency is as follows- Drug/payload conjugation to the unmodified mAb - Site-selective conjugation leading to precise control over DAR and half-life - Diversity of payload (both conventional and novel) including dual payload applications - Stability of linker-payload (minimize off-target, extracellular release of the payload)

11 to 50 staff

Kolon Life Science, Inc. 코오롱생명과학

01 (APIs),(). 02, CDMO. Global Leading Cell & Gene Therapy.

201 to 500 staff

주 다온비에스 L Daon Biosciences

DAON BioSciences) Single Cell & Spatial Genomics 10x Genomics. Single Cell viability sorting WOLF Cell Sorter debris cell enrichment.

11 to 50 staff

세니젠 Sanigen Co., Ltd

51 to 200 staff

Xpertgen Inc. 엑스퍼젠 주식회사

Life science

1 to 10 staff

주 제넨바이오

51 to 200 staff

세랜텍 Celantec

CaBeffect™ Solution Service] Stable cell line construction Gene Cloning Protein expression(bacterial/ Mammalian cell) Antibody production Plasmid DNA preparation

1 to 10 staff